Axio BioPharma is a Contract Development and Manufacturing Organization (CDMO) based in Madison, Wisconsin, dedicated to transforming biopharmaceutical manufacturing through artificial intelligence. The company accelerates the development of mammalian-expressed recombinant proteins, with a particular focus on monoclonal antibodies (mAbs).By leveraging AI-driven process development, Axio BioPharma significantly reduces the timeline from laboratory research to clinical manufacturing, enabling faster delivery of critical therapies.

Core Capabilities:

• AI-Powered Platform: Axio BioPharma’s proprietary AI platform accelerates mAb development by transforming raw sequence data into actionable insights. The platform utilizes intelligent amino acid profiling, self-learning feedback loops, in silico process optimization, and predictive process modeling to enhance quality, scalability, and predictability.

• Process Development: The company designs customized manufacturing strategies for mammalian-expressed proteins, focusing on developing robust, scalable processes that meet specific client requirements.

• Discovery Manufacturing: Axio BioPharma offers small-scale parallel manufacturing services, ranging from 96-well plates to 2 L shake flask expression volumes, to accelerate early-stage discovery programs.

• Research-Grade Manufacturing: The company provides high-quality research-grade protein production to support R&D efforts, ensuring consistent, reproducible results for preclinical studies and early-stage development.

• GMP Manufacturing: In collaboration with strategic partners, Axio BioPharma offers GMP manufacturing services to support clinical development, including process validation, large-scale production, and regulatory support.

Product Offering:

• MKLP1 Pro™ IgM and IgG: Exclusive manufacturing and distribution of MKLP1 Pro antibodies, owned by eMBR Genomics, to support research in midbody biology and early cancer detection.

Axio BioPharma is committed to expanding its capabilities to better serve the biopharmaceutical community. With plans to introduce GMP mammalian manufacturing services by early 2028, the company aims to support clients from early-stage research through to clinical manufacturing, further accelerating the development of life-saving therapies.